The activity of estradiol on the LHRH neuronal network is crucial in the regulation of reproduction. In vivo, estradiol induces galanin (GAL) gene expression in LHRH neurons and GAL/LHRH colocalization is sexually dimorphic and neonatally determined by steroid exposure. The effects of estradiol on LHRH neurons, however, are considered to be indirect because estrogen receptors (ER) have not been detected in LHRH neurons in vivo. Using immortalized mouse LHRH neurons (GT1-7 cells), we demonstrated by RT-PCR and Southern blotting that GT1-7 cells express ER messenger RNA (mRNA). Sequencing of the amplification products indicated that GT1-7 ER is of the ␣-subtype (ER␣). Additionally, estrogen receptors in GT1-7 cells were characterized by competitive radioligand receptor binding and IC 50 values for 17␤-estradiol and ICI-182,780 were found to be 0.24 and 4.1 nM, respectively. The ability of endogenous GT1-7 cell ER to regulate transcription was determined in transient transfection studies using a construct that consisted of a luciferase reporter gene that is driven by tandem estrogen response elements (ERE) and a minimal herpes simplex virus thymidine kinase promoter. 17␤-Estradiol was found to enhance luciferase activity by 2.5-fold at physiological concentrations with an ED 50 value of 47 pM. This induction was completely inhibited by ICI-182,780 which had an IC 50 value of 4.8 nM. Raloxifene, tamoxifen, 4-hydroxytamoxifen, and droloxifene also fully blocked estrogen-mediated luciferase induction with IC 50 values of 58.4, 89.2, 33.2, and 49.8 nM, respectively. In addition, GAL mRNA was detected and identified by RT-PCR followed by Southern blotting using a rat GAL complementary DNA (cDNA) probe. The ability of 17␤-estradiol to modulate expression of the endogenous GAL gene in immortalized LHRH neurons was also determined. Quantitative RT-PCR demonstrated that physiological concentrations of estrogen increase GAL gene expression by 2-fold with an ED 50 value of 23 pM. ICI-182,780, raloxifene, and droloxifene completely blocked this induction.
A VAST literature exists that describes the control of the LHRH neuronal network by estrogens (1) . Indeed, estrogen treatment stimulates LHRH neurons as reflected by an induction of c-fos expression (2) , a hallmark of cellular activity (3) . In addition, our group detected a higher incidence of galanin (GAL) gene expression in LHRH neurons of female rats (4, 5) , indicating that coexpression of GAL and LHRH represents an estrogen-dependent phenomenon. Further studies have provided evidence to indicate that expression of GAL in LHRH neurons is, indeed, dependent on estradiol exposure (6 -9) . More importantly, we have demonstrated that colocalization of GAL and LHRH is sexually dimorphic in terms of both GAL expression in LHRH perikarya (10) and copackaging of both peptides within the same secretory vesicles in the median eminence (7) . Our studies on GAL expression in LHRH neurons, however, did not determine whether or not estrogens exert these actions by acting directly or indirectly on the LHRH neuron. In fact, studies aimed at evaluating the site of action of steroids on the LHRH neuronal network have been confounded by the intrinsic complexity of current models used to assess the problem. The failure to detect estrogen receptors (ER) in LHRH neurons (11, 12) and the identification of estrogenconcentrating neurons in close proximity to LHRH neurons (13, 14) have provided the grounds to establish the dogma that the actions of steroids on the LHRH neuronal system are mediated through regulatory neuronal systems. These interneurons then act as relay stations to transduce steroid inputs that impinge upon the LHRH neuronal network.
Using targeted tumorigenesis, Mellon et al. (15) have established an immortalized LHRH neuronal cell line (GT1 cells), which retains many physiologically relevant features of the LHRH neuron, including regulation of LHRH secretion (16 -18) . It has been reported that immortalized LHRH neurons (GT1-1 subclone) do indeed express estrogen (19, 20) and androgen receptors (19) , suggesting that gonadal steroids could act directly on the LHRH neuronal network.
These observations challenge the current dogma that estradiol exerts its actions on the LHRH neuronal network via interneurons, and they imply that either the technologies used to detect ER in vivo within the LHRH neuronal network may lack sufficient sensitivity, or GT1 cells may not be representative of the LHRH phenotype present in vivo.
In our current studies, we have used a radioligand binding assay and RT-PCR to identify ER protein and messenger RNA (mRNA) in GT1-7 cells. The data indicate that [
125 I]17␤-estradiol labels binding sites and that [
125 I]17␤-estradiol is specifically displaced by ICI-182,780 from these sites. GT1-7 cells also express ER mRNA corresponding to the ligand binding domain of the ER␣-subtype. In addition, the functional activity of ER in GT1-7 cells was determined by transient transfection studies using a minimal estrogen response element (ERE) to regulate a thymidine kinase promoter (tk)-driven luciferase reporter gene. Induction of luciferase activity was ligand-and ERE-dependent, indicating that the expressed receptor is functionally active to enhance transcription. Furthermore, RT-PCR analysis of GT1-7 cell total RNA demonstrated that immortalized LHRH neurons also express GAL mRNA. Because GAL expression in LHRH neurons is exquisitely regulated by estrogen (21, 22) a quantitative RT-PCR (qRT-PCR) method was developed to evaluate estradiol modulation of GAL gene expression in GT1-7 cells. Our data indicate that not only does estradiol, via interaction with ER, regulate GAL gene expression in immortalized LHRH neurons, but, equally as important, that these cells can be stimulated directly by estrogen. Overall, GT1 cells represent a useful model to evaluate the molecular mechanisms of estradiol-dependent activation of LHRH neurons that may occur during the estrous cycle.
Materials and Methods

Cell culture
GT1-7 cells were kindly provided by Dr. Pamela Mellon (University of CA, San Diego, CA). The cells were cultured under standard conditions as described in Moretto et al. (23) . Cells were maintained in growth medium that consisted of high-glucose (4.5 g/liter) DMEM (BioWhittaker, Walkersville, MD) supplemented with 5% horse serum (GIBCO-BRL, Grand Island, NY), 5% FCS (Hyclone, Inc., Logan, UT), 2 mm GlutaMax, I (GIBCO-BRL), 100 U penicillin/ml and 100 g streptomycin/ml (GIBCO-BRL). Cells were grown at 37 C in a humidified incubator in an atmosphere of 5% CO 2 :95% air.
ER and GAL mRNA identification in GT1-7 cells
RT-PCR and Southern blotting were used to detect the presence of ER and GAL mRNA in GT1-7 cells. Mouse brain total RNA (Clontech Laboratories, Inc., Palo Alto, CA) was used as a positive control. Total RNA was isolated from GT1-7 cells using TRIzol (GIBCO-BRL) reagent according to the manufacturer's specifications. Mouse brain and GT1-7 total RNA were treated with DNase I (GIBCO-BRL) under the conditions suggested by the manufacturer.
A primer pair that spans two thirds of the mouse ER␣ ligand binding domain (1079 -1635 bp) (24) was used to reverse transcribe and amplify ER mRNA from total GT1-7 RNA by RT-PCR. The sequences of the primers used were 5Ј CCAAGCCCTCTTGTGATTAAGCACACTAAG 3Ј for the forward primer and 5Ј ACACGGTGGATGTGGTCCTTCTCT-TCCAGAG 3Ј for the reverse primer. The RT reaction consisted of 0.25 g mouse brain or GT1-7 cell total RNA, 2 mm MgCl 2 , 1ϫ PCR buffer (GIBCO-BRL), 1 mm dNTPs, 2 U RNasin (Promega, Madison, WI), 2.5 m reverse primer, 200 U Superscript II reverse transcriptase (GIBCO-BRL) in a final volume of 20 l. Reverse transcriptase was omitted in some reactions to serve as negative controls. One drop of mineral oil was overlaid onto each reaction mixture to prevent evaporation. The reaction mixtures were heated in a thermocycler (MiniCycler, MJ Research, Inc., Watertown, MA) at 42 C for 15 min followed by 99 C for 5 min. The reaction mixtures were cooled and maintained at 4 C until the amplification step. Reaction mixtures from the RT step were prepared for DNA amplication by the inclusion of 0.5 m forward primer, 1.6 mm MgCl 2 , 1ϫ PCR buffer (GIBCO-BRL), and 5 U Taq DNA polymerase (GIBCO-BRL) in a final volume of 100 l. The reactions were heated at 94 C for 3 min followed by 35 rounds of successive heating steps at 94 C for 30 sec, 62 C for 30 sec, and 72 C for 45 sec. Amplification was followed by a final elongation step at 72 C for 5 min. The amplification products were resolved by electrophoresis in a 1% agarose gel using 0.5ϫ Tris-borate-EDTA buffer.
RT-PCR was also used to determine the presence of GAL mRNA in GT1-7 cell total RNA. DNase treatment, RT, and DNA amplification were performed as described above with the following differences. The sequence for the forward and reverse primers for mGAL were 5Ј CCT-GCAAAGGAGAAGAGAGGTTG 3Ј and 5Ј CAGAGGATTGGCTT-GAGGAGTTG 3Ј, respectively. For the RT step, the reaction mixtures consisted of 0.25 g mouse brain total RNA as a positive control and 0.25 or 1 g GT1-7 total RNA, 2.75 mm MgCl 2 , and 0.5 m reverse primer in addition to the components of the DNase I reactions. For the amplification step, the concentrations of the forward primer and MgCl 2 were adjusted to 0.1 m and 2.75 mm, respectively.
DNA was transferred from the agarose gels to Hybond-N ϩ nylon membrane filters (Amersham, Arlington Heights, IL) by vacuum blotting. The filters were washed in 2ϫ SSC for 2 min and dried under vacuum at 80 C. The filters were pre-wetted in dH 2 O and prehybridized for 15 min in 10 ml of Rapid-Hyb (Amersham, Arlington Heights, IL) at 42 C and 65 C for the ER␣ and GAL blots, respectively. An oligonucleotide was synthesized [1305-1323 bp of the published mouse ER␣ sequence (24) ] to serve as a probe for the 557 bp mouse ER amplification product. The mouse ER␣ probe was end-labeled using T4 polynucleotide kinase (GIBCO-BRL) and [␥-
32 P]ATP (3000 Ci/mmol; NEN Life Science Products, Boston, MA) according to standard procedures (25) . A cDNA (532 bp) that includes the entire rGAL sequence was labeled with [␣-32 P]dCTP (3000 Ci/mmol; NEN Life Science Products) by random priming (Random Primers DNA Labeling System; GIBCO-BRL) and used to probe the mGAL amplification product. After addition of the denatured probes, each blot was hybridized for 30 min in 10 ml Rapid-Hyb at the respective prehybridization temperatures. After hybridization, the blot for ER was washed twice in 50 ml 2ϫ SSC with 0.1% SDS for 15 min per wash at room temperature. The mGAL blot was subjected to one 15 min wash in 50 ml 2ϫ SSC with 0.1% SDS at room temperature followed by a more stringent 15 min wash at 65 C in 50 ml 0.5ϫ SSC with 0.1% SDS. After washing, both blots were exposed to a PhosphorImaging screen (Molecular Dynamics, Sunnyvale, CA) and the resulting band intensities visualized using a PhosphorImager and the ImageQuaNT software (Molecular Dynamics).
ER binding analysis
Cells were plated in growth medium at a density of 8 ϫ 10 6 cells/plate on 150-mm Nunc plates precoated with poly-l-lysine (Sigma Chemical Co., St. Louis, MO) and kept in culture until 90% confluent (approximately 4 days). Forty-eight hours before assay, the growth medium was replaced with phenol red-free, charcoal/dextran-stripped serum medium (low steroid medium) and the cells maintained in culture until harvest.
For the receptor preparation, the medium was removed from the plates and the cells were washed twice with 10 ml D-PBS (without Ca ϩϩ or Mg ϩϩ ; BioWhittaker). ER binding buffer (10 mm Tris-HCl, 1 mm EDTA, 1 mm DTT, pH 7.4, 1 ml per plate) was added to each plate and cells were scraped from the plates. The cell material from each plate was pooled and homogenized (30 sec, setting of 3, PT1200 polytron; Brinkmann Instruments, Westbury, NY). The homogenate was spun at 12,000 ϫ g for 10 min. Supernatants were collected, homogenized, and spun at 50,000 ϫ g for 1 h. The supernatant fraction was collected and used for receptor binding analysis. Protein concentration was determined on this cytosolic preparation by the Pierce BCA protein assay, using BSA as the standard (26) .
Binding reactions were prepared in triplicate in 1. and 0.01% (wt/ vol) dextran T500 (Pharmacia Biotechnology, Uppsala, Sweden) to trap unbound steroid. Thereafter, tubes were spun for 3 min at 12,000 ϫ g at 4 C and radioactivity of a 300 l aliquot of supernatant was determined in a gamma counter (ICN Micromedic Systems, Huntsville, AL). The amount of specifically bound radioactivity was calculated by subtracting nonspecific counts from total counts after correcting the data for a total sample volume of 400 l.
Transient transfection and expression of an ER-dependent luciferase reporter gene construct
A plasmid (p294ϩ) containing the luciferase gene (pGL3-Basic, Promega Corporation, Madison, WI) was engineered to express the luciferase gene under the control of the herpes simplex virus tk promoter and two copies of an ERE [the ERE is underlined in the following sequence with vector sequence in lower case letters: 5Ј gctagcGGTCACTGTGAC CAAGATCTCGGTCACTGTGACCagatctctcgagCCCCGCCCACTTGTC ATTGGCGAATTCGAACACGCAGATGCAGTCGGGGCGGCGCGGT CCGAGGTCCACTTCGCATATTAAGGTGACGCGTGTGGCCTCGAA CACCGAGCGaagctt 3Ј]. Plasmid p290ϩ, which has the same sequence as p294ϩ with the exception that it does not contain any ERE or intervening sequences [vector sequence is represented by lower case letters 5Ј gctagctcgagatctctcgagCCCCGCCCACTTGTCATTGGCGAATTCGA ACACGCAGATGCAGTCGGGGCGCGGCGGTCCGAGGTCCACTTC GCATATTAAGGTGACGCGTGTGGCCTCGAACACCGAGCGaagctt 3Ј], was used as a control to determine any ERE/ER-independent activity.
Forty-eight hours before transfection, cells were plated in poly-llysine-coated 24-well culture plates (Nunclon ⌬ SI, InterMed Nunc, Roskilde, Denmark) at 3 ϫ 10 5 cells/well. On the day following plating, the growth medium was removed by aspiration and the cells were washed twice with 1 ml low steroid medium. One milliliter of low steroid medium was added to each well, and the cells were maintained in a humidified environment at 37 C in the presence of 5% CO 2 :95% air for the duration of the studies. After 24 h in low steroid medium, the medium was removed and 1 ml fresh low steroid medium was added to each well. Plasmid DNA was introduced into GT1-7 cells by calcium phosphate-mediated transient transfection that included a glycerol shock (25) . Cells were cotransfected with a ␤-galactosidase reporter gene construct (pSV-␤-galactosidase control vector; Promega) to normalize the data for transfection efficiency. Each well of cells received 100 l of transfection mix that consisted of 1 g p294ϩ or p290ϩ and 0.2 g pSV-␤-galactosidase control vector in 1[times HEPES-buffered saline (HBS; 25 mm HEPES, 140 mm NaCl, 5 mm KCl, 0.75 mm Na 2 HPO 4 , and 6 mm dextrose) containing 125 mm CaCl 2 . Cells were returned to the tissue culture incubator for 4 h. Thereafter, the culture medium containing the transfection mix was removed and 250 l of 15% glycerol in 1ϫ HBS was added to each well. After a 90-sec incubation at 37 C, 1 ml of D-PBS (without Ca ϩϩ or Mg ϩϩ ; GIBCO-BRL) was added to each well and then aspirated. Each monolayer of cells was washed an additional time with 1 ml of D-PBS before 1 ml of fresh low steroid medium was added to each well. Cells were returned to the incubator at 37 C for overnight recovery from the transfection.
The day following the transfection, cells were treated with 17␤-estradiol or 0.1% (vol/vol) ethanol in low steroid medium. 17␤-Estradiol stock solutions were prepared in absolute ethanol. Each drug solution was serially diluted in ethanol to 1000-fold concentrations of the final doses used in the studies. Treatment was begun by replacing low steroid medium with 1 ml low steroid medium containing ethanol vehicle or steroid at the final designated concentrations for the luciferase studies.
After 20 -24 h treatment, each well of cells was washed twice with D-PBS and 100 l of cell lysis buffer (Promega) was overlaid on the cells according to the manufacturer's recommendations. After a 15-min incubation at room temperature, the cells were scraped off and lysates from each well transferred to individual wells of a 96-well V-bottom tissue culture plate. The cell debris was pelleted by centrifugation and the resulting supernatants were assayed for luciferase (20 l lysate) and ␤-galactosidase (5 l lysate) activities by chemiluminescence using the luciferase (Promega) and the Galacto-Light Plus reporter assay systems (Tropix, Bedford, MA), respectively, following the manufacturers' recommendations.
Measurement of estrogen-induced galanin gene expression in GT1-7 cells
For evaluating the effects of estrogen on GAL gene expression, GT1-7 cells were plated in 6-well plates (1.75 ϫ 10 6 cells/well) in growth medium. On the day following plating, the growth medium was removed, the cells were washed once with low steroid medium, and 3 ml fresh low steroid medium was added to each well. Steroid treatments were prepared as described earlier. Treatment was begun 48 h after plating by replacing low steroid medium with 3 ml low steroid medium containing ethanol vehicle or steroid at the final designated concentrations, and cells were incubated for 48 h. At the end of the treatment period, total RNA was isolated from each well of cells using TRIzol reagent (GIBCO-BRL) according to the manufacturer's recommendations and GAL mRNA concentrations were determined by qRT-PCR as described below.
Galanin mRNA expression analysis: quantitative RT-PCR
Mouse galanin mRNA expression was measured by qRT-PCR using an in vitro transcribed mGAL complementary RNA (cRNA) as an amplification standard (GAL sequence: nt 8 -40/268 -410). The mGAL cDNA used to prepare the standard consisted of an internally truncated form of the full-length mGAL cDNA (deletion of bases 40 -268). The mGAL cDNA standard was engineered to conserve the 3Ј and 5Ј priming sites of the full-length mGAL cDNA while providing a shorter amplification product (bases 8 to 39 ϩ bases 269 to 410) than that of the endogenous mRNA. The mGAL cDNA standard was transcribed in vitro using the MEGAscript kit (Ambion, Austin, TX) following the manufacturer's recommendations. After transcription, the truncated mGAL cRNA amplification standard was quantified by UV spectrophotometry and stored as frozen aliquots at Ϫ70 C until used. The concentrations of GT1-7 cell total RNA were determined spectrophotometrically according to standard procedures (25) . The sequences of the forward and reverse primers used in the RT-PCR reactions are 5Ј CAAAGGAGAA-GAGAGGTTGGA 3Ј and 5Ј TTCAAAGCAGAGAACAGAGGA 3Ј, respectively. These primers yield a 173-bp amplification product from the mGAL amplification standard and a 403-bp product from both mouse brain and GT1-7 cell total RNA.
Two sets of reactions were set up for each sample, one with reverse transcriptase and one without, which served as the negative control. The DNase reactions that would contain reverse transcriptase consisted of 10 g GT1-7 cell total RNA, 1ϫ DNase I buffer (GIBCO-BRL), 2 U DNase I (GIBCO-BRL), and 40 fg mGAL amplification standard in a final volume of 20 l. The negative controls that would not contain reverse transcriptase consisted of 2.5 g GT1-7 cell total RNA, 10 fg mGal amplification standard and 1 U DNase I in 1ϫ DNase buffer in a final volume of 10 l. [Amounts of sample RNA and cRNA standard added to the reactions were selected based upon preliminary experiments indicating the range of amounts that would produce similar band intensities among the two species. The sample and cRNA standard amounts differ between reactions with and without reverse transcriptase to maintain identical amounts and concentrations in PCR amplification following dilution of reactions containing reverse transcriptase (as described below).] Mouse brain total RNA (500 ng; Clontech, Palo Alto, CA) was substituted for the GT1-7 mRNA as the positive control. The DNase I reactions were incubated at room temperature for 15 min. After the incubation period, 1 and 2 l of 25 mm EDTA were added to reaction mixtures without and with reverse transcriptase, respectively. All reaction mixtures were incubated at 65 C for 10 min and then held at 4 C in a thermocycler (GeneAmp PCR System 9600, Perkin-Elmer, Norwalk, CT) until used in the RT reactions.
For the RT step, 18 l of the following reagent mixture were added to achieve the following concentrations: 0.5ϫ PCR buffer without Mg ϩϩ (GIBCO-BRL), 3 mm MgCl 2 , 2.2 mm dNTP mix, 5.6 m mGAL reverse primer, 5 U/l Superscript II reverse transcriptase. Each RT-omitted reaction received 9 l of the reagent mixture described above except with the enzyme replaced with 50% (vol/vol) glycerol to achieve final concentrations identical to those of the RT-containing reactions. All reactions were incubated in a thermocycler (GeneAmp PCR System 9600) at 42 C for 15 min, 99 C for 5 min, and then held at 4 C until used in the PCR reactions. For the PCR step, RT-containing samples were prepared by using 20 l (1/2) of each reaction to make five serial 1:1 dilutions resulting in a 1:4 to 1:64 reduction in initial RNA and cRNA amounts, i.e. 2.5 g GT1-7 total RNA and 10 fg mGAL amplification standard in the first tube of the dilution series to 156.3 ng GT1-7 total RNA and 0.625 fg. Reactions without reverse transcriptase were not diluted. Special attention was paid to maintain constant buffer concentrations after the dilutions to the following specification: 0.5ϫ DNase I buffer (GIBCO-BRL), 1.25 mm EDTA, 0.5ϫ PCR buffer (without Mg ϩϩ , GIBCO-BRL), 3 mm MgCl 2 , 1 mm dNTP mix, 2.5 m mGAL reverse primer, 5% (vol/vol) glycerol in a final volume of 20 l. One PCR Gem50 wax bead (Perkin-Elmer) was added to each reaction tube. All reaction mixtures were heated at 75 C for 5 min and then held at 4 C in a thermocycler. Each tube then received the necessary reagents to achieve the concentrations as indicated in a final volume of 100 l: 0.1ϫ DNase buffer (GIBCO-BRL), 0.9ϫ PCR buffer without Mg ϩϩ (GIBCO-BRL), 2 mm MgCl 2 , 0.5 m mGAL forward primer, 0.04 Ci/l [␣-
32 P]dCTP (3000 Ci/mmol; NEN Life Science Products), and 0.025 U/l Taq polymerase (GIBCO-BRL). All tubes were incubated in a thermocycler at 95 C for 3 min. This was followed by 30 cycles of consecutive incubations at 95 C for 20 sec, 56.5 C for 20 sec, and 72 C for 30 sec. After the last cycle, a 5-min elongation step at 72 C was carried out. Under these conditions, target amplification remained in the exponential phase of the amplification [the amount of incorporated nucleotide (cpm) increased with cycle number until cycle number 36. Amount of radioactivity present (cpm; mean Ϯ sem of three determinations) in the GAL band obtained after PCR cycles number 26, 30, 34, 36, 38, and 40 was as follows: 98,536 Ϯ 2,942; 504,550 Ϯ 2,294; 868,065 Ϯ 25,659; 910,673 Ϯ 33,152; 996,055 Ϯ 56,178 and 916,320 Ϯ 5,697, respectively]. Samples were then held at 4 C until the five sample dilutions were analyzed by PAGE. One-fifth of each PCR reaction was separated on a 1.5 mm-thick 5% polyacrylamide:bis acrylamide gel (19:1, polyacrylamide:bis acrylamide; InstaPAGE-19; Kodak, Rochester, NY) at 40 mA per gel at 4 C. The gels were dried on a gel dryer and exposed to phosphor screens (Molecular Dynamics) for 4 h. Band intensities for GT1-7 mGAL and mGAL amplification standard cDNAs were determined using a PhoshorImager SI and ImageQuaNT software (Molecular Dynamics).
Data analysis and statistics
For the receptor binding characterization, a customized JMP (SAS Institute, Inc., Cary, NC) statistical analysis script was developed (Dr. Krishnendu Ghosh, Biometrics, Wyeth-Ayerst Research) to determine the concentrations at which maximal binding of [
125 I]-17␤-estradiol is reduced 50% (IC 50 ) by the competitor. Square root transformation and Huber weighting were applied to all data before performing nonlinear curve fitting to a four parameter logistic model (y ϭ (A-D)/1ϩ (x/C) B ) ϩ D; where y ϭ response, ϫ ϭ nm concentration of drug, A ϭ asymptotic maximum, B ϭ slope factor, C ϭ point of inflection (IC 50 value), and D ϭ asymptotic minimum). Total counts and nonspecific counts were used in the analysis as zero response dose and maximal response dose, respectively. The affinity constant, K i , was calculated for each competitor using the Cheng-Prusoff equation (27) (19) .
In the transfection experiments, luciferase activity was corrected for transfection efficiency by normalizing to ␤-galactosidase activity. For the qRT-PCR experiments, the band intensity data for the GT1-7 cell total RNA and the amplification standard were corrected for the difference in cytosine composition between the full length (GT1-7 cell) and truncated (amplification standard) forms of GAL. For each data set from serially diluted samples, two linear regressions (one for GT1-7 cell GAL bands and one for amplification standard bands) were performed on log-transformed data from which the determination coefficient (R 2 ) and % parallelism between the two generated lines were obtained. The slope for each line was used to calculate a parallelism factor (greater slope/ smaller slope ϫ 100). If both lines are perfectly parallel, this factor would be 100%. Further data evaluation was performed only if the parallelism factor was 75% or better. Thereafter, the band intensities for GAL and amplification standards were pooled and the median value calculated. The regression lines were then used to estimate the amount of GT1-7 RNA and the amount of GAL standard that produces the median band intensity. Thus, the amount of GAL mRNA present in the GT1-7 cell samples was defined as being equal to the amount of standard RNA that produced this median band intensity. For both the transfection and qRT-PCR studies, the mean and se of the mean were calculated for each group of four determinations. Data were fitted to a four-parameter nonlinear regression model (see above) using the SigmaPlot software package (Jandel Scientific). Statistically significant differences were inferred by ANOVA using JMP statistical software (SAS Institute, Cary, NC). The Dunnett's multiple comparison test was used to identify statistically significant differences vs. the control group. A P Ͻ 0.05 was considered as the minimal criteria to define statistically significant differences.
Results
We were able to detect and identify ER␣ mRNA in total RNA isolated from GT1-7 cells that were grown under standard culture conditions (23) by RT-PCR in combination with Southern blot hybridization (Fig. 1, upper panel) . Based on the published mouse ER␣ sequence (24) , the primers that were used produced the expected 557-bp amplification product. The identification of this product as an indicator of the presence of ER mRNA was substantiated by Southern hybridization in which an oligonucleotide that is complementary to region 1305-1323 of the ER␣ ligand binding domain was used as a probe. The 557-bp amplification product, indicative of mouse ER␣ mRNA, was detected by Southern hybridization from RT-PCR reactions with mouse brain total RNA or GT1-7 cell total RNA (Fig. 1, upper panel, lanes 1 and 3,  respectively) . No products were detected in reactions in which reverse transcriptase was omitted (Fig. 1, upper panel,  lanes 2 and 4) , demonstrating that the amplification products originated from mRNA and not from any residual sample DNA contamination. Cloning and subsequent sequencing of the 557 bp amplification product indicated perfect homology to the ER␣ sequence (data not shown).
Competition experiments using radioinert 17␤-estradiol and the antiestrogen ICI-182,780 in the presence of (Fig. 2) . By applying the Cheng-Prusoff equation (27) and using the K d value for ER obtained with GT1-1 cells and 17␤-estradiol (19) , the binding constants (K i values) for 17␤-estradiol and ICI-182,780 were estimated to be 0.86 and 1.45 nm, respectively. Slope factors for the competition curves were not statistically different from one, indicating a ligand receptor interaction that could be explained by a one-site binding model.
The detection of the mRNA for the ER␣ ligand binding domain and estrogen binding sites in LHRH neurons, however, does not affirm the presence of biologically functional ER. Therefore, ER functionality in GT1-7 cells was studied by analyzing its ability to transactivate a heterologous gene. 17␤-Estradiol induced luciferase activity in a dose-depen-dent manner with a 2-to 3-fold increase over control (Fig. 3,  top panel) . Maximal response was observed at 1-100 nm with an estimated potency (EC 50 ) of 47 pm. 17␣-Ethinylestradiol was also effective in inducing luciferase activity with a potency of 17 pm (data not shown). This regulation by estrogens was ERE-dependent because 17␤-estradiol did not induce luciferase activity when GT1-7 cells were transfected with the reporter construct lacking the ERE sequence (Table 1) . To further substantiate ER involvement in the induction of reporter gene expression, GT1-7 cells were treated with the antiestrogen, ICI-182,780, in the presence of the EC 80 concentration (0.2 nm) of 17␤-estradiol. The 17␤-estradiolmediated luciferase induction could be completely inhibited by ICI-182,780 (Fig. 3, bottom panel) , with an IC 50 of 4.8 nm. In contrast, ICI-182,780 treatment alone did not alter luciferase activity when compared with basal levels (Table 1 ). In addition, other ER blockers such as raloxifene, tamoxifen, 4-hydroxytamoxifen, and droloxifene prevented estradiolinduced luciferase activity with varying potencies (Table 2) .
Because GAL gene expression in LHRH neurons is responsive to estrogen exposure and is sexually dimorphic in rats (5), we evaluated the presence of GAL mRNA in immortalized LHRH neurons. The identification of GAL mRNA in GT1-7 cells was accomplished by RT-PCR coupled to Southern blot hybridization (Fig. 1, lower panel) . The primers used for RT-PCR generated a 392-bp product from both mouse brain total RNA and GT1-7 cell total RNA (Fig. 1,  lower panel, lanes 1, 3, and 5) . No product was detected in reactions in which RT was omitted, which indicates that the original template for the 392-bp product was RNA and not contaminating DNA (Fig. 1, lower panel, lanes 2, 4, and 6 ). The PCR product was identified as a portion of the GAL transcript by Southern blot hybridization using a cDNA probe complementary to rat GAL (rGAL). This rGAL cDNA probe has 95% amino acid sequence homology to the mouse GAL (mGAL) sequence.
To characterize the effects of 17␤-estradiol on GAL gene expression in GT1-7 cells, we developed a qRT-PCR method for measuring mGAL mRNA. Quantification by qRT-PCR was deemed necessary because solution hybridization and Northern blot analyses failed to detect any mGAL mRNA and semiquantitative RT-PCR previously detected 17␤-estradiol-induced GAL gene expression in GT1-7 cells with normalization to cyclophilin mRNA levels (22) . Mouse GAL mRNA was normalized to total cellular RNA, a convention also used by others (28) because total RNA did not change significantly over the range of 17␤-estradiol concentrations used (data not shown). The GAL gene-specific primer set chosen for qRT-PCR amplified a 173-bp product from a truncated cRNA amplification standard and a 403-bp product from GT1-7 cell total RNA (Fig. 4, upper left panel) . Band intensity for mGAL is increased by 17␤-estradiol treatment, which is most evident at the lower sample dilutions, (Fig. 4,  upper right panel) , suggesting that 17␤-estradiol increases GAL gene expression in immortalized LHRH neurons. Estrogen-induced GAL gene expression was time dependent. Statistically significant increases in GAL mRNA were detected after as short as 6 h of treatment with 100 nm 17␤-estradiol and approached maximal response by 48 h (Table  3) . Quantification of band intensities reveal that at physiologically relevant concentrations, 17␤-estradiol increased the expression of the GAL gene in a dose-dependent manner (Fig. 4, middle panel) . Maximal expression was obtained at 0.1 nm with a 2-fold increase over control levels (Fig. 4, middle  panel) and an EC 50 value of 23 pm. 17␣-Ethinylestradiol also increased GAL gene expression with a potency of 14 pm (data not shown). This induction by estrogens was ER-specific because the antiestrogen ICI-182,780 was completely effective (IC 50 ϭ 30.2 nm) in blocking the induction of GAL mRNA produced by 1 nm 17␤-estradiol (Fig. 4, lower panel) . ICI-182,780 treatment alone (1 m) did not alter GAL mRNA concentrations when compared with basal levels (Table 1) . Other antiestrogens such as raloxifene and droloxifene also inhibited 17␤-estradiol induction of GAL gene expression (Table 2) . Thus, it appears that GT1-7 cells produce functionally active ER that may be directly involved in the regulation of GAL gene expression.
Discussion
We have previously demonstrated that GAL is localized in LHRH neurons and that this colocalization is sexually dimorphic and neonatally determined by steroid exposure (10) . In this regard, estradiol induces colocalization of GAL in LHRH neurons (4), emphasizing the potential role of estro- TABLE 1 . 17␤-estradiol-induced luciferase activity is EREdependent while ICI-182,780 has no effect on luciferase activity or galanin gene expression in immortalized LHRH neurons. b Cell were transiently transfected with a luciferase reported construct that either lacked an ERE (ϪERE) or contained two copies of an ERE (ϩERE).
c At least two independent experiments were done in quadruplicate and data are shown as the mean Ϯ SEM from representative experiments. gens in the regulation of GAL gene expression in LHRH neurons. Indeed, GAL expression is sensitive to estrogen in the hypothalamic pituitary axis. The mechanism by which estrogen influences GAL gene expression in LHRH neurons, however, is poorly understood. Previous efforts by several investigators to demonstrate the presence of ER in LHRH neurons have been hampered by technical limitations and by the paucity and scattered distribution of endogenous LHRH neurons (11, 12) . Consequently, the effects of estradiol on the LHRH neuronal network were thought to be indirect. However, the 5Ј flanking region of the human LHRH gene was found to confer estrogen responsiveness to a luciferase reporter gene (29) . In addition, purified ER from calf uterus was found by DNase footprinting to bind to this region (29) . These findings suggest that if LHRH neurons do indeed produce functional ER, the necessary cis-acting elements are present in the LHRH gene for ER-dependent regulation. It is extremely difficult from a molecular perspective to delineate the mechanism(s) by which estradiol elicits ER-dependent gene expression in vivo in the LHRH neurons. To circumvent these difficulties, we set out to investigate the nature by which estradiol modulates GAL gene expression using immortalized LHRH neurons, i.e. GT1-7 cells, and to ascertain any direct involvement of biologically active ER in this event.
By using RT-PCR followed by Southern hybridization we were able to detect and positively identify the presence of ER␣ mRNA transcripts in GT1-7 cells. The ER present in these immortalized LHRH neurons was determined to be functionally active for both ligand binding and gene transactivation capabilities. In whole cell binding experiments, Poletti et al. (19) determined that ERs are present in another subclone of the GT cells (GT1-1). ER in immortalized LHRH neurons are low in abundance (B max value of 6.2 fmol/mg total cell protein) but have a high affinity (K d value of 0.11 nm) for [
3 H]estradiol (19) . The low binding capacity (B max ) of ER in GT1 cells compared with MCF-7 cells (60 fmol/mg cytosolic protein) (30, 31) , may help to explain why previous in vivo studies failed to detect ER in LHRH neurons (11, 12, 32) . Our radioligand binding studies support the findings of Poletti et al. (19) by demonstrating a high affinity ER in GT1-7 cells. In addition, we have expanded the characterization of this receptor by demonstrating ligand dependency of the GT1-7 ER through homologous and nonhomologous competition studies using nonradioisotopic 17␤-estradiol and ICI-182,780, respectively. Each compound competitively in- (31, 33, 34) ]. Because LHRH neurons are not concentrated in distinct nuclei in the hypothalamus and we found that RT-PCR was necessary to detect ER␣ mRNA, it is possible that the techniques previously employed to identify ER in vivo were not sufficiently sensitive to detect this receptor in LHRH neurons. Similar confounding conditions existed in bone biology until ER in estrogenresponsive osteoblast-like cells (200 -1600 binding sites per nucleus) were detected by using more sensitive methods than the conventional approaches used in the past (35, 36) .
Additional scenarios can be envisioned that reconcile the apparent discrepancies in the detection of ER in hypothalamic LHRH neurons in vivo compared with immortalized LHRH neurons. For example, because GT1 cells were isolated from tumors produced through targeted oncogenesis (15) , in which the expression of SV40 T-antigen oncogene is directed by the regulatory regions of the LHRH gene, it is possible that GT1 cells represent hypothalamic LHRH neurons during a particular fetal stage when LHRH and ER are coexpressed. These neurons may become less abundant or absent as development progresses and, therefore, the lack of detection of appreciable hypothalamic LHRH neurons that express ER in the adult animal may be an accurate depiction. Alternatively, the number of hypothalamic LHRH neurons that express ER may be low in number throughout development and immortalization of one of these neurons by targeted tumorigenesis was fortuitous. This case, as well, is in concordance with the established in vivo findings.
Identification of ER␣ mRNA and estradiol binding sites does not preclude the existence of ER that are incapable of mediating transcriptional activation. Nonfunctional ERs have been identified that bind steroid but are incapable of nuclear binding and activation of gene transcription (37) (38) (39) . Therefore, it was of paramount importance to demonstrate that the ER␣ produced by GT1-7 cells is biologically functional. To this end, we have shown by transient transfection experiments that although endogenous ER␣ is in low abundance in GT1-7 cells, it can be activated sufficiently by the ligand to drive transcription of the luciferase reporter gene through an ERE-dependent mechanism. Although the construct we used contains a consensus vitellogenin ERE, the fact that receptor activation is mediated by physiological concentrations of estradiol indicates that LHRH neurons may respond to estrogen under in vivo conditions by activating or repressing particular genes. The fact that ICI-182,780 and other antiestrogens specifically block this response suggests that this effect is ER dependent. In addition, estrogen treatment of GT1-7 neurons results in elevated androgen receptor binding sites (19) , which reinforces the functionality of ER present in immortalized LHRH neurons.
Previous work has demonstrated that GAL expression in LHRH neurons in adult rats is sexually dimorphic with more GAL-containing LHRH neurons present in females than in males (5, 7) as well as higher GAL mRNA content in LHRH neurons in females than males (40) . Colocalization of GAL and LHRH is profoundly influenced by estrogen. In rats, ovariectomy reduces the amount of LHRH neurons expressing GAL from 80% in intact female animals to approximately 15% and this reduction is reversed by estrogen treatment (6) . Likewise, GAL mRNA concentrations are reduced in LHRH neurons of ovariectomized adult rats, but can be restored to control levels by administration of physiological concentrations of estradiol (8) . With the establishment of the presence of ER in both the GT1-7 and GT1-1 cell lines (19) , the foundation is partially laid to support the premise that estrogen can directly regulate GAL expression in a subpopulation of LHRH neurons. We found that steroid treatment resulted in elevated GAL gene expression in GT1-7 cells with a detectable increase in GAL mRNA occurring after only 6 h of 17␤-estradiol treatment. This rapid response to estrogen treatment suggests that ER-mediated transcriptional activation of the GAL gene may play a role in the increase in GAL mRNA; however, we cannot rule out changes in transcript stability as a possible mechanism for this effect. In addition to 17␤-estradiol, several other estrogens, such as estrone, ⌬ 8, 9 dehydroestradiol, 17␤, ⌬ 8,9 dehydroestradiol, or 17␣-ethinylestradiol, increase GAL gene expression (41, 42) . In other tissues, estrogen also has been shown to enhance GAL gene expression. For example, GAL produced in the rat anterior pituitary is known to be sensitive to estrogen (43) (44) (45) . Kaplan and co-workers (43) have demonstrated that pharmacological doses of 17␤-estradiol increased pituitary rGAL mRNA in both male and ovariectomized female rats by as much as 4000-fold. Furthermore, the GAL gene was cloned and identified as an estrogen-inducible gene from estrogen-induced pituitary tumor mRNA (44) . The mechanism(s) by which estrogen-induced GAL gene transcription occur(s), however, has not been fully elucidated. One can envision that the liganded ER␣ induces GAL gene activation by directly binding to cis-acting enhancer element(s) in the GAL promoter. In this respect, the cow (46), rat (47) , and mouse (48) GAL genes have been sequenced recently. Whereas in the rGAL gene promoter region one can identify 3 half-palindromic ERE sites (47) , the mGAL and bovine gene promoters appear to contain a single half ERE site (5Ј GGTCA 3Ј) (46, 48) . GenBank identifies this half-palindromic ERE site as being located at bases 504 -508 (GenBank accession no. L38575) in the mouse sequence. Whether this site is responsible for ER-dependent activation of the GAL gene on its own or in combination with other trans-acting entities is currently unknown. In support of a direct ER-DNA interaction resulting in GAL gene activation, Howard et al. (49) have reported that, in gel mobility shift assays, one of two ERE consensus regions that they identified in the human GAL gene bound recombinant human ER␣ as well as nuclear extract protein from either rat anterior pituitary tissue or rat pituitary tumor cells (MtTW). The ability of this ERE consensus region to modulate gene expression was not determined; however, the availability of the regulatory sequences from mouse, rat, and human GAL genes has made it possible to design gel mobility shift assays and heterologous gene transcription activation studies to determine the role of these putative ERE regions in the regulation of GAL gene expression.
The results from our transient transfection studies support a direct role of estrogen in regulating LHRH neuronal gene expression because endogenous ERs present in GT1-7 cells were found to be capable of activating luciferase gene tran-scription through a conventional ERE-dependent mechanism. Indeed, it has been reported that half-palindromic ERE sites identified in the rat and human GAL gene promoter have ER-dependent transcriptional activation capabilities (50, 51) . It is interesting to note that the half-palindrome of the consensus ERE (5Ј GGTCA 3Ј) is present as a functional ERE in the chicken ovalbumin gene promoter (52) . This sequence (5Ј TGGGTCA 3Ј), which is present in both the chicken ovalbumin gene (53) and rGAL gene promoters (51) , that has been shown to be a binding site for a constitutive protein complex containing c-fos and c-jun that coactivates gene transcription in the presence of ER␣ and estrogen (53) . Gaub and co-workers found that the ER␣-mediated activation of the ovalbumin gene through the fos/jun complex does not require the ER␣ DNA binding domain and, therefore, conclude that direct ER␣ interaction with genomic elements is not required for this system (53) . We can envision several scenarios for ER activation of GAL gene expression. These include a direct activation through receptor-DNA interactions and/or an indirect activation through ER-response modulator(s) complexes that bind to DNA through response modulator(s) contacts. Given these findings, further analyses of the cis-and trans-acting elements that regulate GAL gene expression are clearly warranted to elucidate the mechanism(s) by which estrogen directly and indirectly regulates gene expression in LHRH neurons and to determine whether or not these effects are tissue specific.
In conclusion, immortalized LHRH neurons possess the characteristics of target cells for estrogen activity. They express ER␣ mRNA and produce ER that displays specific and saturable binding to 17␤-estradiol that is inhibited competitively by the antiestrogen, ICI-182,780. The ER present in GT1-7 was also able to transcriptionally activate a reporter gene through a classical ER-dependent mechanism. In addition, the endogenous GAL gene was found to be induced by 17␤-estradiol through an increase in GAL mRNA. Because estrogen was demonstrated to mediate gene transactivation in cultured GT1-7 cells (in the absence of other cell types) and that GT1-7 cells do, indeed, produce functional ER, these findings strongly support the scenario that, in addition to any indirect actions, estrogen may also exert its effects directly on hypothalamic LHRH neurons.
